MedTrace Logo

Kagocel® for the Prevention of ARVI and Influenza in Young People

NCT04626622 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2020-11-12

No results posted yet for this study

Summary

This study evaluates the use of Kagocel for the prevention of acute respiratory viral infections (ARVI) and influenza during the epidemic rise in the incidence of diseases in Russia in 2018 (epidemiology: the number of cases during the period of Kagocel administration and follow-up, bacterial exacerbations, the number of repeated episodes (reinfection), demographics of patients, safety, adherence to treatment) in students at risk due to stress, lack of sleep and fatigue.

Conditions

  • Acute Upper Respiratory Tract Infection
  • Influenza
  • Respiratory Viral Infection

Interventions

DRUG

Kagocel

Investigators could prescribe other drugs in frame of routine clinical practice

DRUG

No one

Investigators don't prescribe any antiviral drugs in frame of routine clinical practice

Sponsors & Collaborators

  • Nearmedic Plus LLC

    lead INDUSTRY

Principal Investigators

  • Elena Tikhonova, Dr. habilitated, Professor · Department of infectious diseases and epidemiology of Krasnoyarsk State Medical University named after Prof. V.F.Voino-Yasenetsky

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-15
Primary Completion
2018-04-26
Completion
2018-06-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04626622 on ClinicalTrials.gov